B. Helfrich

发表

Epidermal growth factor receptor family in lung cancer and premalignancy.

F. Hirsch, P. Bunn, W. Franklin, 2002, Seminars in oncology.

EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines.

F. Hirsch, P. Bunn, W. Franklin, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression of catalytically inactive phospholipase Cbeta disrupts phospholipase Cbeta and mitogen-activated protein kinase signaling and inhibits small cell lung cancer growth.

P. Bunn, L. Heasley, B. Helfrich, 1998, Cancer research.

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.

P. Bunn, D. Raben, D. Chan, 2002, Seminars in oncology.

Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer?

D. Raben, B. Helfrich, 2004, Clinical lung cancer.

Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.

F. Hirsch, P. Bunn, W. Franklin, 2002, Clinical breast cancer.

A randomized study of the efficacy of adjuvant local graft irradiation following renal transplantation.

A. Dritschilo, K. Harter, B. Helfrich, 1990, International journal of radiation oncology, biology, physics.

Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a “biased agonist” mechanism

J. Stewart, P. Bunn, T. Puck, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Native and rearranged ALK copy number and rearranged cell count in non–small cell lung cancer

W. Franklin, M. Varella‐Garcia, R. Doebele, 2013, Cancer.

EGFR-related genomic abundance associates with EGFR mutation in non-small cell lung cancer and is accurately detected by interphase FISH

J. Minna, A. Gazdar, P. Bunn, 2006 .

C225 anti-epidermal growth factor receptor (EGFR) monoclonal antibody sensitizes human non-small cell lung cancer to both radiation and chemotherapy cytotoxicity in-vitro and in-vivo

F. Hirsch, P. Bunn, W. Franklin, 2001 .

Discordant Signal Transduction and Growth Inhibition of Small Cell Lung Carcinomas Induced by Expression of GTPase-deficient G(*)

P. Bunn, L. Heasley, G. Johnson, 1996, The Journal of Biological Chemistry.

Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo

P. Bunn, D. Gao, Jihye Kim, 2016, Molecular Cancer Therapeutics.

Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.

J. Stewart, P. Bunn, Kenneth K. Chan, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux.

Y. Miller, P. Bunn, W. Franklin, 1996, Cancer research.

Bradykinin-related compounds as new drugs for cancer and inflammation.

E. York, J. Stewart, P. Bunn, 2002, Canadian journal of physiology and pharmacology.

Enzastaurin a protein kinase Cbeta-selective inhibitor, inhibits the growth of SCLC and NSCLC cell lines.

F. Hirsch, P. Bunn, D. Chan, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of a Novel CD 56 Lymphokine-activated Killer Cell Precursor in Cancer Patients Receiving Recombinant Interleukin 2 '

R. Fisher, P. Simms, B. Helfrich, 2006 .

Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.

R. Fisher, P. Simms, B. Helfrich, 1992, Cancer research.

Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.

R. Fisher, P. Simms, B. Helfrich, 1989, Journal of immunology.

Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know.

P. Bunn, D. Raben, F. Ciardiello, 2003, Lung cancer.

Reversal of anticancer multidrug resistance by the ardeemins.

W. Bornmann, A. Zatorski, B. Helfrich, 1998, Proceedings of the National Academy of Sciences of the United States of America.

PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines

B. Helfrich, I. Nakachi, L. Heasley, 2016, Clinical and translational science.

Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma

P. Bunn, D. Raben, B. Frederick, 2007, Molecular Cancer Therapeutics.

Effects of recombinant neutral endopeptidase (EC 3.4.24.11) on the growth of lung cancer cell lines in vitro and in vivo.

Y. Miller, P. Bunn, D. Chan, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non–Small Cell Lung Cancer Cell Lines

Chan Zeng, F. Hirsch, P. Bunn, 2006, Molecular Cancer Research.

Age-related changes in the degeneracy of the mouse T-cell repertoire.

B. Helfrich, M. Segre, D. Segre, 1989, Cellular immunology.

Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas

F. Hirsch, P. Bunn, W. Franklin, 2002, British Journal of Cancer.

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

J. Minna, L. Girard, A. Gazdar, 2006, Cancer research.

Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines.

T. Chou, P. Bunn, L. Heasley, 1999, Cancer research.

Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.

P. Bunn, D. Gao, Jihye Kim, 2012, Cancer research.

A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop

Katherine R. Singleton, A. Tan, L. Heasley, 2013, Oncogenesis.

Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression

Trista K. Hinz, Lynn E. Heasley, R. Doebele, 2010, PloS one.

ZEB1-responsive genes in non-small cell lung cancer.

Elizabeth Garrett-Mayer, Michael Mitas, P. Bunn, 2011, Cancer letters.

The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.

T. K. Johnson, P. Bunn, W. Franklin, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells

P. Bunn, L. Heasley, R. Nemenoff, 2009, Molecular Pharmacology.

Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.

P. Bunn, D. Raben, B. Helfrich, 2004, International journal of radiation oncology, biology, physics.

Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment

P. Harari, D. Raben, F. Ciardiello, 2002, Expert review of anticancer therapy.

FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies

F. Hirsch, P. Bunn, R. Dziadziuszko, 2014, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFRTKI Sensitivity across All LungCancer Histologies

F. Hirsch, P. Bunn, R. Dziadziuszko, 2014 .

Antitumor Activity of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non–Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFR Mutations but not EGFR Protein Levels

Chan Zeng, Adi Gazdar, J. Minna, 2006, Clinical Cancer Research.

Radiant heat-induced hyperthermia in mice: in vivo effects on the immune system.

C. Cain, B. Helfrich, M. Segre, 1992, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.

F. Hirsch, P. Bunn, W. Franklin, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy

P. Bunn, D. Gao, B. Helfrich, 2018, Lung cancer.

Altered HOX and WNT7A expression in human lung cancer.

P. Bunn, E. Brambilla, W. Franklin, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Bradykinin antagonists as new drugs for prostate cancer.

E. York, J. Stewart, P. Bunn, 2002, International immunopharmacology.

AntitumorActivityof the EpidermalGrowth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non^Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFRMutations but not EGFRProtein Levels

A. Gazdar, F. Hirsch, P. Bunn, 2006 .

Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors.

G. Piazza, P. Bunn, A. Baron, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition

P. Bunn, Jihye Kim, A. Tan, 2016, Clinical Cancer Research.

New lung cancer drugs from bradykinin antagonists.

E. York, D. Chan, B. Helfrich, 2004, Chest.

Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer.

G. Piazza, K. Kelly, P. Bunn, 2002, Seminars in oncology.

FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies

P. Bunn, R. Dziadziuszko, D. Gao, 2014, Clinical Cancer Research.

The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.

P. Bunn, W. Franklin, A. Baron, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

288 POSTER The selective Aurora B kinase inhibitor AZD1152 inhibits in vitro growth in small cell lung cancer (SCLC) cell lines

P. Bunn, B. Helfrich, J. Haney, 2008 .